Prokarium is a biopharmaceutical company focused on developing vaccination solutions based on synthetic biology. Our oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. Prokarium’s vision is that all protein vaccines can be delivered orally. As well as reducing costs and time to manufacture vaccines, in addition to carrying vaccines to temperatures up to 40 degrees. Prokarium’s headquarters based in Keele, UK, and Prokarium ‘s expertise extends from microbiology and immunology to pharmaceutical mergers and acquisitions in business development.